SG11201406526WA - Cyclic bridgehead ether dgat1 inhibitors - Google Patents

Cyclic bridgehead ether dgat1 inhibitors

Info

Publication number: SG11201406526WA
Authority: SG; Singapore
Prior art keywords: bridgehead; cyclic; ether; dgat1 inhibitors; dgat1
Prior art date: 2012-04-27

Application number

SG11201406526WA

Other languages

English (en)

Inventor

Xin Chen

Yiping Ding

Rohit Duvadie

Yu Gai

Tyler Harrison

Qian Liu

Jay Larrow

Justin Yik Ching Mao

Sejal Patel

Jiong Ye

Frederic Zecri

Xuchun Zheng

Rui Zheng

Yizong Zhou

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-04-27

Filing date

2013-04-25

Publication date

2014-11-27

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48577190&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201406526W(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2013-04-25 Application filed by Novartis Ag filed Critical Novartis Ag

2014-11-27 Publication of SG11201406526WA publication Critical patent/SG11201406526WA/en

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/08—Bridged systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Diabetes (AREA)
Hematology (AREA)
Obesity (AREA)
Endocrinology (AREA)
Emergency Medicine (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Gastroenterology & Hepatology (AREA)
Dermatology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Psychiatry (AREA)
Child & Adolescent Psychology (AREA)
Virology (AREA)
Ophthalmology & Optometry (AREA)
Hospice & Palliative Care (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Plural Heterocyclic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

SG11201406526WA 2012-04-27 2013-04-25 Cyclic bridgehead ether dgat1 inhibitors SG11201406526WA (en)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US201261639341P	2012-04-27	2012-04-27
US201361787695P	2013-03-15	2013-03-15
CN2013072735		2013-03-15
PCT/IB2013/053292 WO2013160873A1 (fr)	2012-04-27	2013-04-25	Inhibiteurs de dgat1 à ponts éthers cycliques

Publications (1)

Publication Number	Publication Date
SG11201406526WA true SG11201406526WA (en)	2014-11-27

Family

ID=48577190

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SG11201406526WA SG11201406526WA (en)	2012-04-27	2013-04-25	Cyclic bridgehead ether dgat1 inhibitors

Country Status (26)

Country	Link
US (2)	US8993619B2 (fr)
EP (1)	EP2852590B1 (fr)
JP (1)	JP6042529B2 (fr)
KR (1)	KR20150013194A (fr)
CN (1)	CN104395309B (fr)
AP (1)	AP3592A (fr)
AR (1)	AR090859A1 (fr)
AU (1)	AU2013254307B2 (fr)
BR (1)	BR112014026760A8 (fr)
CA (1)	CA2870336A1 (fr)
CL (1)	CL2014002822A1 (fr)
CO (1)	CO7111275A2 (fr)
CR (1)	CR20140494A (fr)
EA (1)	EA025050B1 (fr)
EC (1)	ECSP14030538A (fr)
ES (1)	ES2624291T3 (fr)
IL (1)	IL235313A0 (fr)
MA (1)	MA37439B1 (fr)
MX (1)	MX357768B (fr)
PE (2)	PE20160802A1 (fr)
PH (1)	PH12014502413A1 (fr)
SG (1)	SG11201406526WA (fr)
TN (1)	TN2014000425A1 (fr)
TW (1)	TW201348239A (fr)
UY (1)	UY34767A (fr)
WO (1)	WO2013160873A1 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DK3243826T3 (da)	2012-04-26	2020-02-03	Bristol Myers Squibb Co	Imidazothiadiazol-og imidazopyrazinderivater som proteaseaktiverede receptor 4- (par4) hæmmere til behandling af blodpladeaggregation
TWI568722B (zh)	2012-06-15	2017-02-01	葛蘭馬克製藥公司	作爲ｍＰＧＥＳ－１抑制劑之三唑酮化合物
CA2897200C (fr)	2013-01-14	2021-07-06	Incyte Corporation	Composes de carboxamide aromatique bicyclique utiles comme inhibiteurs de pim kinase
KR102311840B1 (ko)	2013-01-15	2021-10-14	인사이트 홀딩스 코포레이션	Pim 키나제 저해제로서 유용한 티아졸카복스아마이드 및 피리딘카복스아마이드 화합물
US8962660B2 (en)	2013-03-14	2015-02-24	Bristol-Myers Squibb Company	Oxabicyclo [2.2.2] acid GPR120 modulators
JP2016528298A (ja)	2013-08-23	2016-09-15	インサイト・コーポレイションＩｎｃｙｔｅＣｏｒｐｏｒａｔｉｏｎ	Ｐｉｍキナーゼ阻害剤として有用なフロピリジン及びチエノピリジンカルボキシアミド化合物
US9822124B2 (en)	2014-07-14	2017-11-21	Incyte Corporation	Bicyclic heteroaromatic carboxamide compounds useful as Pim kinase inhibitors
US9580418B2 (en)	2014-07-14	2017-02-28	Incyte Corporation	Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
CN104292190B (zh) *	2014-09-03	2016-05-04	哈尔滨工业大学	一种β-溴代四氢呋喃类化合物的合成方法
CN104292189B (zh) *	2014-09-03	2016-05-04	哈尔滨工业大学	一种β-丙二酸二乙酯取代四氢呋喃类化合物的合成方法
US9540347B2 (en)	2015-05-29	2017-01-10	Incyte Corporation	Pyridineamine compounds useful as Pim kinase inhibitors
AR105967A1 (es)	2015-09-09	2017-11-29	Incyte Corp	Sales de un inhibidor de pim quinasa
WO2017059251A1 (fr)	2015-10-02	2017-04-06	Incyte Corporation	Composés hétérocycliques utiles en tant qu'inhibiteurs de la kinase pim
AR113922A1 (es)	2017-12-08	2020-07-01	Incyte Corp	Terapia de combinación de dosis baja para el tratamiento de neoplasias mieloproliferativas
US20210317131A1 (en) *	2018-09-18	2021-10-14	Bristol-Myers Squibb Company	Oxabicyclo acids as lpa antagonists

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TW200303742A (en)	2001-11-21	2003-09-16	Novartis Ag	Organic compounds
WO2004078163A2 (fr)	2003-02-28	2004-09-16	Transform Pharmaceuticals, Inc.	Compositions pharmaceutiques a base d'un co-cristal
AR044399A1 (es)	2003-05-20	2005-09-14	Novartis Ag	Compuestos heterociclicos y su uso como activadores de receptores de ppar. composiciones farmaceuticas que los contienen
US7915252B2 (en) *	2004-08-06	2011-03-29	Merck Sharp & Dohme	Sulfonyl compounds as inhibitors of 11-beta-hydroxysteroid dehydrogenase-1
MX2008012406A (es) *	2006-03-31	2008-10-07	Novartis Ag	Compuestos nuevos.
AU2008339570B2 (en) *	2007-12-20	2012-04-12	Astrazeneca Ab	Carbamoyl compounds as DGAT1 inhibitors 190
PT2781516T (pt) *	2010-10-07	2017-03-15	Novartis Ag	Novas formas cristalinas do sal de sódio do ácido (4-{4-[5-(6-trifluorometil-piridin-3-ilamino)-piridin-2-il]-fenil}-ciclo-hexil)-acético
US8962660B2 (en) *	2013-03-14	2015-02-24	Bristol-Myers Squibb Company	Oxabicyclo [2.2.2] acid GPR120 modulators

2013
- 2013-04-25 CA CA2870336A patent/CA2870336A1/fr not_active Abandoned
- 2013-04-25 EP EP13727385.0A patent/EP2852590B1/fr not_active Not-in-force
- 2013-04-25 PE PE2016000359A patent/PE20160802A1/es not_active Application Discontinuation
- 2013-04-25 ES ES13727385.0T patent/ES2624291T3/es active Active
- 2013-04-25 AU AU2013254307A patent/AU2013254307B2/en not_active Ceased
- 2013-04-25 JP JP2015507656A patent/JP6042529B2/ja not_active Expired - Fee Related
- 2013-04-25 PE PE2014001902A patent/PE20150724A1/es not_active Application Discontinuation
- 2013-04-25 MA MA37439A patent/MA37439B1/fr unknown
- 2013-04-25 MX MX2014013002A patent/MX357768B/es active IP Right Grant
- 2013-04-25 KR KR1020147032910A patent/KR20150013194A/ko not_active Application Discontinuation
- 2013-04-25 BR BR112014026760A patent/BR112014026760A8/pt not_active Application Discontinuation
- 2013-04-25 WO PCT/IB2013/053292 patent/WO2013160873A1/fr active Application Filing
- 2013-04-25 EA EA201491970A patent/EA025050B1/ru not_active IP Right Cessation
- 2013-04-25 CN CN201380034256.8A patent/CN104395309B/zh not_active Expired - Fee Related
- 2013-04-25 SG SG11201406526WA patent/SG11201406526WA/en unknown
- 2013-04-25 AP AP2014008018A patent/AP3592A/xx active
- 2013-04-26 US US13/871,586 patent/US8993619B2/en not_active Expired - Fee Related
- 2013-04-26 AR ARP130101409A patent/AR090859A1/es unknown
- 2013-04-26 TW TW102115141A patent/TW201348239A/zh unknown
- 2013-04-26 UY UY0001034767A patent/UY34767A/es not_active Application Discontinuation
2014
- 2014-10-13 TN TN2014000425A patent/TN2014000425A1/fr unknown
- 2014-10-20 CL CL2014002822A patent/CL2014002822A1/es unknown
- 2014-10-23 IL IL235313A patent/IL235313A0/en unknown
- 2014-10-27 CO CO14237492A patent/CO7111275A2/es active IP Right Grant
- 2014-10-27 PH PH12014502413A patent/PH12014502413A1/en unknown
- 2014-10-27 CR CR20140494A patent/CR20140494A/es unknown
- 2014-11-27 EC ECIEPI201430538A patent/ECSP14030538A/es unknown
2015
- 2015-02-20 US US14/628,205 patent/US20150166563A1/en not_active Abandoned

Also Published As

Publication number	Publication date
UY34767A (es)	2013-11-29
CA2870336A1 (fr)	2013-10-31
PH12014502413A1 (en)	2015-01-12
CO7111275A2 (es)	2014-11-10
MX357768B (es)	2018-07-24
CN104395309B (zh)	2016-09-28
ES2624291T3 (es)	2017-07-13
US8993619B2 (en)	2015-03-31
EA201491970A1 (ru)	2015-03-31
JP6042529B2 (ja)	2016-12-14
EA025050B1 (ru)	2016-11-30
AR090859A1 (es)	2014-12-10
EP2852590B1 (fr)	2017-02-01
TW201348239A (zh)	2013-12-01
KR20150013194A (ko)	2015-02-04
MA37439A1 (fr)	2016-07-29
PE20150724A1 (es)	2015-05-17
AU2013254307A1 (en)	2014-10-30
US20130289058A1 (en)	2013-10-31
BR112014026760A2 (pt)	2017-06-27
AP3592A (en)	2016-02-15
IL235313A0 (en)	2014-12-31
AU2013254307B2 (en)	2016-05-26
US20150166563A1 (en)	2015-06-18
AP2014008018A0 (en)	2014-10-31
CR20140494A (es)	2015-03-13
PE20160802A1 (es)	2016-09-03
BR112014026760A8 (pt)	2018-01-16
JP2015514798A (ja)	2015-05-21
EP2852590A1 (fr)	2015-04-01
CL2014002822A1 (es)	2015-04-24
MX2014013002A (es)	2015-01-22
MA37439B1 (fr)	2017-02-28
WO2013160873A1 (fr)	2013-10-31
TN2014000425A1 (en)	2016-03-30
ECSP14030538A (es)	2015-11-30
CN104395309A (zh)	2015-03-04

Publication	Publication Date	Title
IL235313A0 (en)	2014-12-31	Bridgehead cyclic sites that inhibit dgat1
HK1212984A1 (zh)	2016-06-24	咪唑並吡啶化合物
HK1206737A1 (en)	2016-01-15	Cyclic ether pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use -4---
GB2501897B (en)	2014-09-03	Injection devices
AU347191S (en)	2013-02-22	Adapter
IL234845A0 (en)	2014-12-31	Isocazole as a beta-lactamase inhibitor
GB201317141D0 (en)	2013-11-06	Well Isolation
GB2507645B (en)	2017-01-11	Collet
SG11201501173SA (en)	2015-05-28	PI3Kδ INHIBITOR
DK2623146T3 (en)	2017-01-23	Injection devices
HUE051648T2 (hu)	2021-03-29	CCR3-gátlók használata
GB201219753D0 (en)	2012-12-19	Injection devices
EP2934518A4 (fr)	2016-08-31	Inhibiteurs de la cetp spirocycliques
HK1211927A1 (en)	2016-06-03	Aggrecanase inhibitors
HK1209422A1 (en)	2016-04-01	Fbxo3 inhibitors fbxo3
GB201220965D0 (en)	2013-01-02	Light-projecting devices
HK1216924A1 (zh)	2016-12-09	饋通件
EP2834054A4 (fr)	2015-10-14	Base de barboteur
EP2822721A4 (fr)	2015-10-21	Adaptateur
AU4878P (en)	2014-08-06	MiniMaca Macadamia tetraphylla
GB201203309D0 (en)	2012-04-11	Storage devices
ZA201209341B (en)	2013-09-25	Gasification
AU344015S (en)	2012-08-24	Adapter
GB201204760D0 (en)	2012-05-02	Easy tees
GB201205325D0 (en)	2012-05-09	o2o